证券代码：603229 证券简称：奥翔药业 公告编号：2026-002 浙江奥翔药业股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/27 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 年 月 23 日 | 1 | 月 | 24 | 日~2026 | 1 | | 预计回购金额 | 5,000万元~10,000万元 | | | | | | | 回购价格上限 | 13.90元/股 | | | | | | | 回购用途 | □减少注册资本 √用于股权激励和/或员工持股计划 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 实际回购股数 | 5,201,200股 | | | | | | | 实际回购股数占总股本比例 | 0.63% | ...

Group 1 - The core viewpoint of the news is that Aoxiang Pharmaceutical experienced a slight decline in stock price and has notable financing activities, indicating a mixed sentiment among investors [1] - On January 16, Aoxiang Pharmaceutical's stock fell by 0.79%, with a trading volume of 75.74 million yuan. The net financing purchase for the day was 574,400 yuan, with a total financing and securities balance of 392 million yuan [1] - The financing balance of Aoxiang Pharmaceutical accounts for 4.72% of its market capitalization, which is above the 70th percentile of the past year, indicating a relatively high level of financing [1] Group 2 - Aoxiang Pharmaceutical, established on April 22, 2010, specializes in the research, production, and sales of specialty APIs and intermediates, with a revenue composition that includes liver disease (31.29%), cardiovascular (18.94%), and antibacterial (18.56%) products [2] - For the period from January to September 2025, Aoxiang Pharmaceutical reported a revenue of 646 million yuan, a year-on-year decrease of 6.40%, and a net profit attributable to shareholders of 207 million yuan, down 9.59% year-on-year [2] - As of September 30, 2025, Aoxiang Pharmaceutical had 32,000 shareholders, an increase of 5.64% from the previous period, with an average of 25,948 circulating shares per person, a decrease of 5.34% [2] Group 3 - Aoxiang Pharmaceutical has distributed a total of 286 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [3] - As of September 30, 2025, Hong Kong Central Clearing Limited was the ninth largest circulating shareholder of Aoxiang Pharmaceutical, holding 5.36 million shares, an increase of 160,600 shares from the previous period [3]

Core Viewpoint - The company, Aoxiang Pharmaceutical, is actively expanding its international business presence and aims to enhance its market penetration in regions such as Europe, America, Japan, and South Korea [2] Group 1 - The company exports its products to various countries and regions, including Europe, America, Japan, and South Korea [2] - Aoxiang Pharmaceutical plans to deepen its international business layout [2] - The company aims to further increase its international market penetration rate [2]

分红方面，奥翔药业A股上市后累计派现2.86亿元。近三年，累计派现2.07亿元。 融资方面，奥翔药业当日融资买入956.91万元。当前融资余额4.00亿元，占流通市值的4.81%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，奥翔药业1月6日融券偿还3.26万股，融券卖出600.00股，按当日收盘价计算，卖出金额 6012.00元；融券余量3.47万股，融券余额34.77万元，低于近一年20%分位水平，处于低位。 资料显示，浙江奥翔药业股份有限公司位于浙江省化学原料药基地临海园区东海第四大道5号，成立日 期2010年4月22日，上市日期2017年5月9日，公司主营业务涉及特色原料药及医药中间体的研发、生产 和销售,以及为客户提供定制生产和研发业务。主营业务收入构成为：肝病类31.29%，心脑血管类 18.94%，抗菌类18.56%，痛风类11.46%，其他6.85%，前列腺素类4.84%，技术服务费2.79%，神经系统 类2.39%，抗肿瘤类1.43%，高端氟类1.37%，呼吸系统类0.06%，其他业务收入0.01%。 截至9月30日，奥翔药业股东户数3.20万，较上期增加5.64%；人均流通股2 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603229 证券简称：奥翔药业 公告编号：2026-001 浙江奥翔药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 | 回购方案首次披露日 | 2025/1/27 | | --- | --- | | 回购方案实施期限 | 2025/1/24~2026/1/23 | | 预计回购金额 | 5,000万元~10,000万元 | | 回购用途 | □减少注册资本 √用于股权激励和/或员工持股计划 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 5,201,200股 | | 累计已回购股数占总股本比例 | 0.63% | | 累计已回购金额 | 50,006,023.36元 | | 实际回购价格区间 | 7.52元/股~11.39元/股 | 一、回购股份的基本情况 浙江奥翔药业股份有限公司（以下简称"公司"）于 2025 年 1 月 24 日召开 第四届董事会第六次会议，审议通过了《关于以集中竞价交易方 ...

Group 1 - Aoxiang Pharmaceutical has received approval from the National Medical Products Administration for the marketing of palbociclib and dagagliflozin active pharmaceutical ingredients [1] - Palbociclib is the first CDK4/6 inhibitor approved for cancer treatment, specifically for HR+ positive and HER2- negative locally advanced or metastatic breast cancer, with a projected global sales of approximately $4.367 billion in 2024 [1] - Dagagliflozin is a new oral hypoglycemic agent that can improve blood sugar control and reduce cardiovascular risks in heart failure patients, with an expected global sales of about $7.72 billion in 2024 [1] Group 2 - Aoxiang Pharmaceutical provides non-patent infringing process design, development, and regulatory submission services for generic drug manufacturers, gaining recognition in regulated markets like the US, Europe, and Japan [2] - The raw material drug sector is considered a core part of the pharmaceutical industry, with the quality of raw materials directly impacting the safety and efficacy of final drugs [2] - The trend of developing countries like China and India improving their raw material drug capabilities is evident, with advancements in research and production technology [2] Group 3 - R&D innovation is crucial for the sustainable development of pharmaceutical companies in China, especially in the face of challenges like patent expirations and centralized procurement [3] - Optimizing processes and enhancing quality for generic raw materials is essential for Chinese pharmaceutical companies to transition towards high-end specialty raw materials and innovative drugs [3]

Group 1 - Zijin Mining expects a net profit of approximately 51-52 billion yuan for 2025, representing a year-on-year increase of about 59%-62% due to growth in gold, copper, and silver production and sales prices, along with a significant increase in lithium carbonate production [1] - Tianpu Co. has seen its stock price rise by 718.39% from August 22 to December 30, leading to a suspension for stock trading review due to significant deviation from the company's fundamentals [1] - Salt Lake Co. plans to acquire 51% of Wenkang Salt Lake for 4.605 billion yuan, which will enhance its competitive edge in lithium and potassium resource development [1] Group 2 - Mingde Bio intends to acquire 100% of Wuhan Bikaier Rescue Supplies Co. in a cash transaction, which is expected to constitute a major asset restructuring [2] - Jiamei Packaging has announced that it may apply for a trading suspension if its stock price continues to rise abnormally, despite no significant changes in its fundamentals [2] Group 3 - Jinpan Technology signed a contract worth approximately 696 million yuan for an overseas data center project, which is expected to positively impact the company's long-term performance [3] Group 4 - China Pharmaceutical plans to acquire 70% of Zezheng Pharmaceutical for 525 million yuan [4] - Shengxin Lithium Energy intends to acquire 30% of Qicheng Mining for 2.08 billion yuan to increase its control over Huirong Mining [5] - China Aluminum's subsidiary plans to acquire 51% of Yun Aluminum Logistics for 264 million yuan [5]

Group 1 - China Medical plans to acquire 70% equity of Zezheng Pharmaceutical for 525 million yuan to enhance its R&D capabilities in the pharmaceutical sector [1] - Hongchang Electronics has commenced production of its functional high-end copper-clad laminate electronic materials project [2] - China State Construction has secured multiple major projects totaling 32.09 billion yuan, which represents 1.5% of its audited revenue for 2024 [3] Group 2 - China Resources Double Crane has established an industrial fund with a committed investment of 83 million yuan, targeting a total fundraising goal of 500 million yuan [4] - Pinggao Electric and its subsidiaries have won state grid procurement projects worth approximately 876 million yuan, accounting for 7.06% of its 2024 revenue [5] - Dong'an Power received a government subsidy of 2.47 million yuan, with 1.47 million yuan related to assets and 1 million yuan related to income [6] Group 3 - Nantian Information has paid overdue taxes and penalties totaling 50.31 million yuan, which will impact its net profit for 2025 [7] - Erli Six has changed its investment plan to establish a wholly-owned subsidiary in Hong Kong for submarine cable business with an investment of 320 million yuan [8] - Dream Lily plans to invest 170 million yuan in an e-commerce warehouse project at its East US factory [9] Group 4 - Shen Shen Fang A's controlling shareholder has terminated the agreement to transfer 7.07% of the company's shares to Dongfang Asset, with no change in control [10] - Tianfu Culture has signed strategic cooperation framework agreements with various cultural and tourism bureaus to promote film and tourism integration [11] - Jinzi Tianzheng's chairman has resigned due to work adjustments, but will continue to fulfill his duties until a new chairman is elected [12] Group 5 - Jiangshan Oupai and its subsidiaries received government subsidies totaling 10.04 million yuan, with 7.51 million yuan related to income [13] - Ninghu Expressway plans to increase its investment in Jiangsu Danjin Expressway Co., Ltd. by 128 million yuan to support highway construction [14] - Jiangyin Bank has received approval for the qualifications of its employee director and vice president [15] Group 6 - Aoxiang Pharmaceutical has received approval for the listing application of two chemical raw materials [16] - Daye Co. has not yet commenced mass production of its robotic tendon products, with ongoing uncertainties in technology and profitability [17] - Rongsheng Environmental has proposed a cash dividend of 3.8 yuan per 10 shares, totaling approximately 97.36 million yuan [19] Group 7 - Yunyi Electric plans to invest 66 million USD in Morocco to establish a wholly-owned subsidiary and production base [20] - Derun Electronics has reached an agreement regarding the delayed payment of 100 million yuan in equity transfer funds [21] - Baihua Pharmaceutical is planning a change in control, leading to a continued suspension of its stock [22] Group 8 - CITIC Bank's executive director and president has resigned due to work adjustments [23] - Haizike's subsidiary has received acceptance for clinical trial applications for two innovative drugs [24] - Tianrun Dairy's subsidiaries received government subsidies totaling 21.53 million yuan, representing 49.32% of its net profit for 2024 [25] Group 9 - Andisou plans to issue 398 million A-shares at 7.54 yuan per share, raising a total of 3 billion yuan [26][27] - Fuda Co. has completed the transfer of its 50% stake in a joint venture, which is expected to positively impact its 2025 financial results [28] - Jianghua Micro has received environmental approval for a project to produce 37,000 tons of ultra-pure wet electronic chemicals [29] Group 10 - Nanwang Technology received a government subsidy of 10 million yuan, accounting for 0.66% of its net assets for 2024 [30] - Changgao Electric New has won state grid procurement projects totaling 161 million yuan, representing 9.14% of its 2024 revenue [31] - Huaxin Precision plans to invest up to 600 million yuan of idle funds in low-risk financial products [32] Group 11 - Fuguang Co. received a government subsidy of 1.26 million yuan for basic research projects, which is 13.27% of its net profit for 2024 [33] - Benli Technology has obtained a drug production license, which will help optimize its product structure [34] - Jintuo Co. proposed a cash dividend of 4.1 yuan per 10 shares, totaling approximately 99.48 million yuan [35] Group 12 - Kang Enbei has elected a new chairman and vice chairman during its board meeting [36] - Sanyuan Bio has completed the construction and installation of equipment for the remaining capacity of its 20,000-ton alulose project [38]

Core Viewpoint - The approval of the raw materials for Palbociclib and Dapagliflozin indicates compliance with national drug registration requirements, enhancing the company's product line and competitiveness, and promoting sustainable and healthy development [2]. Group 1: Product Approvals - The company received the approval notice for the raw materials of Palbociclib and Dapagliflozin from the National Medical Products Administration [1]. - Palbociclib is a CDK4/6 inhibitor used for treating hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer [1]. - Dapagliflozin is an SGLT-2 inhibitor used for improving blood sugar control and reducing cardiovascular risks in adults with heart failure [1]. Group 2: Strategic Implications - The approval of these raw materials will enrich the company's product line, enhancing its competitiveness in the pharmaceutical market [2]. - The introduction of these drugs is expected to contribute to the company's continuous, stable, and healthy development [2].

Core Viewpoint - Aoxiang Pharmaceutical (603229) has received approval from the National Medical Products Administration for the marketing of its active pharmaceutical ingredients, Palbociclib and Dapagliflozin [1] Group 1 - The company announced the receipt of the approval notice for the marketing application of Palbociclib and Dapagliflozin [1]